Midwest Cardiovascular Research Foundation

Amplitude Vascular Systems Enrolls First Patient in POWER PAD II Intravascular Lithotripsy Trial

7 months ago

• Amplitude Vascular Systems (AVS) has enrolled the first patient in the POWER PAD II trial, evaluating the Pulse IVL system for calcified peripheral arterial disease. • The POWER PAD II study, which received FDA IDE approval in June 2024, aims to enroll up to 120 patients across 20 U.S. facilities over six months. • The Pulse IVL system is designed for easy delivery across complex calcified lesions, potentially reducing procedural costs and improving patient outcomes. • The trial's results could pave the way for a new treatment option using intravascular lithotripsy (IVL) therapy for patients with severely calcified arterial disease.